CMXC - Cell MedX Corp.

Other OTC - Other OTC Delayed Price. Currency in USD
0.1900
0.0000 (0.00%)
At close: 10:53AM EDT
Stock chart is not supported by your current browser
Previous Close0.1900
Open0.1900
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1900 - 0.1900
52 Week Range0.0500 - 0.3000
Volume5,000
Avg. Volume4,054
Market Cap8.414M
Beta (3Y Monthly)-0.60
PE Ratio (TTM)N/A
EPS (TTM)-0.0230
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Newsfile2 months ago

    Cell MedX Signs Definitive Worldwide Distribution Rights Agreement with Live Current Media, Inc.

    Carson City, Nevada--(Newsfile Corp. - March 27, 2019) - Cell MedX Corp. (OTCQB: CMXC), Cell MedX Corp. ("Cell MedX" or the "Company"), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, announced today that on March 21, 2019, the Company entered into a definitive agreement for exclusive worldwide distribution rights of the ebalance device for home-use ("the "Agreement") with Live Current Media, Inc. ("LIVC"), ...

  • Newsfile3 months ago

    Cell MedX Corp. Provides an Update on Progress Toward US Premarket Clearance and Clarifies its eBalance Certification

    Carson City, Nevada--(Newsfile Corp. - February 12, 2019) - Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company"), an early development stage biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness is pleased to announce significant progress toward obtaining premarket clearance in the US for its eBalance device. The eBalance device is not yet available for sale in the US.The Company has been ...

  • Newsfile5 months ago

    Cell MedX Corp. Enters into Credit Line Agreement and Issues Warrants

    Carson City, Nevada--(Newsfile Corp. - December 31, 2018) - Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company"), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, announces that on December 27, 2018, the Company entered into an Agreement with Mr. Richard Jeffs (the "Lender"), the Company's major shareholder (the "Agreement"), for an unsecured line of credit of up to ...

  • Newsfile5 months ago

    Cell MedX Corp. Manufactures eBalance Devices in Canada

    Carson City, Nevada--(Newsfile Corp. - December 12, 2018) -  Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company"), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness is pleased to announce that it has successfully completed its first 100 Canadian manufactured eBalance devices.Upon receiving its Certificate of Conformity, qualifying the eBalance devices as Class A (professional use) and Class B ...

  • Newsfile6 months ago

    Cell MedX Corp. Receives Safety and Electrical Certifications for the eBalance Pro Device

    Carson City, Nevada--(Newsfile Corp. - December 4, 2018) -  Cell MedX Corp. (OTCQB: CMXC), Cell MedX Corp. ("Cell MedX" or the "Company"), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, announced today that the Company received electrical and safety certification for the Company's eBalance Pro device (the "Device"). The Company has received a Certificate of Conformity, from LabTest Certification Inc., ...

  • Newsfile8 months ago

    Cell MedX Corp Signs Letter of Intent for Worldwide Distribution Rights and Enters into Royalty Agreement Contracts

    Carson City, Nevada--(Newsfile Corp. - September 14, 2018) - Cell MedX Corp. (OTCQB: CMXC), Cell MedX Corp. ("Cell MedX" or the "Company"), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, announced today that on September 10, 2018, the Company entered into a non-binding letter of intent (the "LOI") with Live Current Media, Inc. ("LIVC"), an arms-length party, for worldwide distribution rights of ...